These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23836623)

  • 21. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Khan OA; Tselis A; Boster A
    Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
    [No Abstract]   [Full Text] [Related]  

  • 22. Equivalence approaches.
    Williams RL; Chen ML; Hauck WW
    Clin Pharmacol Ther; 2002 Sep; 72(3):229-37. PubMed ID: 12235443
    [No Abstract]   [Full Text] [Related]  

  • 23. Composite and multicomponent end points in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2017 Dec; 36(28):4437-4440. PubMed ID: 28675919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardizing end points in perioperative trials: towards a core and extended outcome set.
    Myles PS; Grocott MP; Boney O; Moonesinghe SR;
    Br J Anaesth; 2016 May; 116(5):586-9. PubMed ID: 27106961
    [No Abstract]   [Full Text] [Related]  

  • 26. Some remaining challenges regarding multiple endpoints in clinical trials.
    Snapinn S
    Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies.
    Levin LA; Sengupta M; Balcer LJ; Kupersmith MJ; Miller NR
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):30. PubMed ID: 34846515
    [No Abstract]   [Full Text] [Related]  

  • 28. The superiority of patient engagement and shared decision-making in noninferiority trials.
    Hoffman RM; McNaughton-Collins M
    J Gen Intern Med; 2014 Jan; 29(1):16-7. PubMed ID: 23979687
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the impact of endpoint shopping on power in confirmatory clinical trials.
    Wiens BL
    J Biopharm Stat; 2003 May; 13(2):229-40. PubMed ID: 12729391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of multiple ordinal endpoints.
    Häberle L; Pfahlberg A; Gefeller O
    Biom J; 2009 Feb; 51(1):217-26. PubMed ID: 19197963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A note on tree gatekeeping procedures in clinical trials.
    Dmitrienko A; Tamhane AC; Liu L; Wiens BL
    Stat Med; 2008 Jul; 27(17):3446-51. PubMed ID: 18484599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events in clinical trials: is a new approach needed?
    Barrios V; Escobar C; Prieto L; Herranz I
    Lancet; 2008 Aug; 372(9638):535-6. PubMed ID: 18707983
    [No Abstract]   [Full Text] [Related]  

  • 35. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fire in the hole: carotid stenting versus endarterectomy.
    Kinlay S
    Circulation; 2011 Jun; 123(22):2522-5. PubMed ID: 21606395
    [No Abstract]   [Full Text] [Related]  

  • 37. Noninferiority hypotheses and choice of noninferiority margin.
    Ng TH
    Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging standards in statistical practice: implications for clinical trials in rehabilitation medicine.
    Millis SR
    Am J Phys Med Rehabil; 2003 Oct; 82(10 Suppl):S32-7. PubMed ID: 14502037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.